Clinical trial
Prospective, National, Multicentric, Observational Study to Evaluate the Safety, Efficacy and Quality of Life of Patients With Atrial Fibrillation, Treated With Trombix® (Rivaroxaban).
NCT06184204 is registered in ClinicalTrials.gov with Beker Laboratories as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective, National, Multicentric, Observational Study to Evaluate the Safety, Efficacy and Quality of Life of Patients With Atrial Fibrillation, Treated With Trombix® (Rivaroxaban).
- Lead sponsor
- Beker Laboratories
- Phase
- Observational
- Overall status
- Completed
- Start date
- December 18, 2023
- Completion date
- June 22, 2025
- Enrollment
- 398 (actual)
- Sites
- 17
Conditions
As the registry lists them; a condition with its own page is linked.